DarioHealth Reports Fourth Quarter and Full year 2024 Financial and Operating Results
Rhea-AI Summary
DarioHealth (DRIO) reported strong financial results for Q4 and full-year 2024, with annual revenue increasing 32.9% to $27.0 million. The company's B2B2C channel showed remarkable growth, with recurring revenues rising 300% year-over-year. Q4 2024 revenue reached $7.6 million, up 110% from Q4 2023.
Key highlights include completion of a $25.6 million equity financing, resulting in a $34.5 million proforma cash balance. Operating loss decreased by 35% to $11.7 million (GAAP) in Q4 2024. The company added 36 new employer and health plan clients in 2024, bringing total client base to 83, with a projected 50% net client growth in 2025.
Following the Twill acquisition, Dario expanded its AI-powered platform to support five chronic conditions. The company expects to achieve operational cash flow breakeven by end of 2025, supported by an anticipated 20% reduction in operating expenses. Gross margins exceeded 80% in the B2B2C business over the past three quarters.
Positive
- Revenue increased 32.9% YoY to $27.0 million in 2024
- B2B2C recurring revenue grew 300% YoY to $20.0 million
- Secured $25.6 million equity financing with $34.5 million proforma cash balance
- Operating loss decreased 35% in Q4 2024
- Added 36 new clients with 90%+ retention rate
- Gross margins exceeded 80% in B2B2C business
Negative
- Operating loss of $11.7 million in Q4 2024
- Net loss of $9.6 million in Q4 2024
- Operating expenses increased 10.6% YoY to $15.9 million in Q4
- Some accounts may not renew as company optimizes client mix
Insights
DarioHealth's Q4/FY2024 results demonstrate accelerating transformation toward a sustainable, high-margin business model. The 32.9% revenue growth to
The financial trajectory shows significant operational improvements. Gross margins expanded dramatically to
The
The strategic acquisition of Twill has strengthened Dario's competitive position, creating an integrated platform addressing five chronic conditions. This positions the company to capitalize on two major market trends: the consolidation of digital health vendors and the growing demand for GLP-1 medication support services - addressing what has become employers' top healthcare expense.
Dario's results reveal a company successfully executing the challenging transition from direct-to-consumer to an enterprise-focused model with SaaS-like economics. This shift addresses a fundamental challenge in digital health - creating sustainable economics while delivering clinical value.
Their integration of the Twill acquisition deserves particular attention. Rather than just adding a mental health point solution, Dario has created a unified platform addressing the interconnected nature of chronic conditions. The expansion through Rula's network of 15,000 providers creates a compelling hybrid model combining AI-driven digital interventions with human therapeutic support - essential for sustainable engagement.
The 90%+ client retention rate is particularly noteworthy in a market where employers and health plans are actively consolidating their digital health portfolios. This suggests Dario is demonstrating tangible ROI and becoming embedded in their clients' healthcare ecosystems.
Their strategic pivot toward GLP-1 support represents excellent market timing. As medications like Wegovy and Ozempic rapidly scale, healthcare purchasers face unprecedented cost pressures, creating demand for services that optimize medication effectiveness through behavioral support. By leveraging data from 5 million patients and billions of data points, Dario can deliver the personalized interventions needed to maximize outcomes.
The company's emphasis on AI implementation across its organization signals potential for both improved user experiences and operational efficiencies. Their collaboration with Sanofi further validates their platform approach, creating a recurring revenue stream from pharmaceutical partnerships beyond their core employer and health plan business.
- Full-year 2024 revenue increased by
32.9% to$27.0 million $20.4 million - Revenue growth driven by B2B2C channel including employers and health plans resulting in recurring revenues which increased by
300% year over year as core business continues to gain traction. - Completed
$25.6 million $34.5 - Revenue growth and efficient post-merger integration resulted in a decrease in operating loss in the quarter ended December 31, 2024, of
35% to$11.7 million 24% to$6.9 million - Company expects to realize an additional
20% reduction in operating expenses between the fourth quarter of 2024 and the fourth quarter of 2025 through further post-merger consolidation and implementation of AI tools across the organization. - Advancements in Dario's AI-powered platform and expansion post-Twill acquisition have created one of the most comprehensive product portfolios in the industry, aligning with the market consolidation and shift towards whole-person care as well as GLP-1 cost management.
- 2024 growth in B2B2C channel included 36 new employers and health plans client wins, bringing the total client base to 83; forecasting
50% net client growth in 2025. - Dario will host an investor conference call and webcast at 8:30 a.m. ET today.
Over the past year, Dario continued its transformational shift, evolving into a leading healthcare technology company operating under a Software as a Service ("SaaS")-like model with high margin, recurring revenues based on multi-year contracts across a large, growing, diversified base of clients. With a focus on continuous developments, enhancements to and expansion of its technology and product offerings, Dario solidified its reputation as a premier platform in the business-to-business-to-consumer ("B2B2C") market, as evidenced by expanding sales to employers, health plans, and strategic partners.
The acquisition of Twill Inc. ("Twill")—Dario's most significant to date—further strengthened its leadership in the industry, creating one of the most comprehensive, clinically integrated digital health platforms. Now supporting five chronic conditions under a single, unified brand, we believe that Dario is uniquely positioned to meet the growing demand for consumer-centric, whole-person care in an increasingly value-driven healthcare environment. Dario has significantly strengthened its financial profile, driving greater efficiency, scalability, and profitability, and these advancements are reflected in our gross margins exceeding
"Our strategic initiatives yielded remarkable financial improvements throughout 2024 in both our top and bottom line. We are already seeing this positive trajectory continue into 2025. For the full year of 2024, total revenue reached
While we are excited about our top line growth, profitability cannot be achieved through revenue growth alone. With a dual focus on revenue and expense efficiency, we implemented focused cost-management strategies that led to a
"In 2024, Dario won 36 new clients by capitalizing on the market's demand for comprehensive chronic care solutions to address their most expensive and challenging conditions. Dario's current business model and product offering satisfies this demand with its whole-person approach. This demand is driven by a focus on member engagement and achieving strong return on investment (ROI), with organizations looking to consolidate their digital health investments into high-value, cost-effective solutions that improve outcomes across a broad population.
Concurrently, there is growing demand for solutions that complement GLP-1 therapies, as employers and health plans acknowledge the need for long-term behavioral and lifestyle support beyond medication alone. Reports show that GLP-1 medications were the top healthcare expense for employers in 2024, making cost management an urgent priority. With our broad and mature portfolio, Dario is uniquely positioned to capitalize on these trends and deliver meaningful impact for both members and customers. GLP-1 therapies are evolving beyond weight loss, with emerging research pointing to new applications in cardiovascular health, neurodegenerative diseases, addiction treatment, and even certain cancers. As part of this transformation, Dario is getting closer to care by expanding our GLP-1 capabilities through our collaboration with MediOrbis, adding prescribing services to provide a more clinically integrated experience.
Finally, Dario is uniquely positioned to meet the demand for AI-driven efficiencies in digital health. We continue to advance AI-driven innovation to increase its impact while improving care in a hyper-personalized manner. By leveraging our data from 5 million patients, 25 years of user journeys, and billions of data points to enhance engagement, optimize operations, and drive better clinical and financial outcomes—an area we intend to expand further," said Steven Nelson, Chief Commercial Officer of Dario.
"In 2024, Dario saw a record-breaking expansion across employers, health plans, and pharmaceutical companies," continued Steven Nelson, "We secured 36 new contracts and grew our total client base to 83 organizations, reinforcing the strong demand for our multi-condition, AI-powered platform. This momentum is a testament to our unmatched ability to engage users, drive sustained behavior change, and deliver tangible ROI.
Additionally, our client renewal rate remains above
Our approach remains centered on driving engagement, improving outcomes, and ensuring the highest return on investment for our clients, which we believe positions us well for sustained growth in 2025 and beyond.
We have also expanded Dario Mind, formerly known as Twill, by integrating with Rula, one of the largest virtual therapist networks in the U.S. Through this collaboration, Dario members now have access to Rula's extensive network of over 15,000 providers, covering 120 million lives. By combining Rula's in-network provider reach with Dario's AI-driven digital health solutions, we are making high-quality mental health support more accessible and easier to implement for employers and health plans. This strategic expansion strengthens our ability to deliver a truly integrated, whole-person digital health experience, further reinforcing Dario's leadership in the evolving healthcare landscape.
Looking ahead to 2025, we expect to accelerate growth by expanding our reach into mid-sized employers, while continuing to capture large-scale health plan opportunities and maximizing the value of our existing collaborations. We are working closely with current health plan clients to expand and enhance our product offerings, aligning them with their healthcare cost reduction goals by leveraging digital health to drive better outcomes and more efficient care delivery. Beyond client wins, Dario's revenue model has never been more diversified, reflecting a stronger financial foundation and reduced dependency on any single client. Our expanded employer, health plan, and pharmaceutical collaborations ensure greater revenue predictability, resilience, and scalability.
One example of this is our strategic collaboration with Sanofi which has evolved into a recurring revenue model, providing a stable, high-value revenue stream as we enter 2025. This revenue model demonstrates the confidence that industry leaders have in Dario's ability to continuously deliver value over time to them and their users, highlighting our opportunity to significantly grow this market in the future.
"Momentum has continued into early 2025, with 9 new client wins, which we believe underscores the strength of our market position and the growing demand for our solutions," said Steven Nelson, Chief Commercial Officer of Dario. "Building on this momentum, we aim to expand our total client base in 2025 by an additional
Fourth Quarter 2024 Results Summary
Revenues for the three months ended December 31, 2024, were
B2B2C, employers and health plans recurring revenues for the three months ended December 31, 2024, were
Gross profit for the three months ended December 31, 2024, was
Pro-forma gross profit, excluding
Total operating expenses for the three months ended December 31, 2024, were
Total operating expenses excluding stock-based compensation, acquisition related expenses and depreciation for the three months ended December 31, 2024, were
Operating loss for the three months ended December 31, 2024, was
Financing income was
Net loss was
Net loss excluding stock-based compensation, acquisition related expenses and depreciation for the three months ended December 31, 2024 was
A reconciliation of GAAP to non-GAAP measures has been provided in the financial statement tables included in this press release. An explanation of these measures is also included below under the heading "Non-GAAP Financial Measures."
Full Year 2024 Results Summary:
Revenues for the twelve months ended December 31, 2024, were
B2B2C, employers and health plans recurring revenues for the twelve months ended December 31, 2024, were
Gross profit for the twelve months ended December 31, 2024, was
Pro-forma gross profit, excluding
Total operating expenses for the twelve months ended December 31, 2024, were
Operating loss for the twelve months ended December 31, 2024, increased by
Financing income was
Net loss was
Net loss excluding stock-based compensation, acquisition related expenses and depreciation for the twelve months ended December 31, 2024, was
A reconciliation of GAAP to non-GAAP measures has been provided in the financial statement tables included in this press release. An explanation of these measures is also included below under the heading "Non-GAAP Financial Measures."
Conference Call Details: Monday, March 10, 8:30am ET
Dial-in Number: 1-800-717-1738 (domestic) or 1-646-307-1865 (international)
Call me™: https://emportal.ink/41htore
Participants can use the dial-in numbers above and be answered by an operator OR click the Call me™ link for instant telephone access to the event. This link will be made active 15 minutes prior to the scheduled start time.
Webcast link: https://viavid.webcasts.com/starthere.jsp?ei=1708830&tp_key=417ae4f4c3
Participants are asked to dial in approximately 10 minutes prior to the start of the event. A replay of the call will be available approximately two hours after completion of the conference call through Monday, March 24th, 2025. To listen to the replay, dial 1-844-512-2921 (domestic) or 1-412-317-6671 (international) and use replay passcode 1134608.
About DarioHealth Corp.
DarioHealth Corp. (Nasdaq: DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. Our platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.
Our user-centric platform offers people continuous and customized care for their health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results and making the right thing to do the easy thing to do.
Dario provides its highly user-rated solutions globally to health plans and other payers, self-insured employers, providers of care and consumers. To learn more about Dario and its digital health solutions, or for more information, visit http://dariohealth.com.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of the Company related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discuss that its cash balance will be sufficient to fund operations through operational cash flow breakeven run rate by the end of 2025 with significant cushion; that it expects to generate an additional
Non-GAAP Financial Measures
We have provided in this release financial information that has not been prepared in accordance with Generally Accepted Accounting Principles (GAAP). These non-GAAP financial measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similar measures presented by other companies. We use these non-GAAP financial measures internally in analyzing our financial results and believe they are useful to investors, as a supplement to GAAP measures, in evaluating our ongoing operational performance. We believe that the use of these non-GAAP financial measures provides an additional tool for investors to use in evaluating ongoing operating results and trends and in comparing our financial results with peer companies, many of which present similar non-GAAP financial measures to investors.
Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. Investors are encouraged to review the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures provided in the financial statement tables below.
Operating expenses (non-GAAP). Our presentation of non-GAAP operating expenses excludes stock-based compensation expenses, amortization of acquisition related expenses and depreciation of fixed assets. Due to varying available valuation methodologies, subjective assumptions, and the variety of equity instruments that can impact a company's non-cash operating expenses, we believe that providing non-GAAP financial measures that exclude non-cash expenses provides us with an important tool for financial and operational decision making and for evaluating our own core business operating results over different periods of time.
Net loss (non-GAAP). Our presentation of adjusted net loss excludes the effect of certain items that are non-GAAP financial measures. Adjusted net loss represents net loss determined under GAAP without regard to stock-based compensation expenses, deferred inventory, depreciation of fixed assets, earn-out remeasurement and acquisition related expenses and amortization. We believe these measures provide useful information to management and investors for analysis of our operating results.
DARIOHEALTH CORP. AND ITS SUBSIDIARIES | ||||||
CONSOLIDATED BALANCE SHEETS | ||||||
December 31, | December 31, | |||||
2024 | 2023 | |||||
ASSETS | ||||||
CURRENT ASSETS: | ||||||
Cash and cash equivalents | $ | 27,764 | $ | 36,797 | ||
Short-term bank deposits | 697 | - | ||||
Short-term restricted bank deposits | 175 | 292 | ||||
Trade receivables, net | 4,804 | 3,155 | ||||
Inventories | 4,753 | 5,062 | ||||
Other accounts receivable and prepaid expenses | 2,336 | 2,024 | ||||
Total current assets | 40,529 | 47,330 | ||||
NON-CURRENT ASSETS: | ||||||
Deposits | 79 | 6 | ||||
Operating lease right of use assets | 1,065 | 967 | ||||
Long-term assets | 313 | 143 | ||||
Property and equipment, net | 709 | 899 | ||||
Intangible assets, net | 18,762 | 5,404 | ||||
Goodwill | 57,427 | 41,640 | ||||
Total non-current assets | 78,355 | 49,059 | ||||
Total assets | $ | 118,884 | $ | 96,389 | ||
DARIOHEALTH CORP. AND ITS SUBSIDIARIES | ||||||
CONSOLIDATED BALANCE SHEETS | ||||||
December 31, | December 31, | |||||
2024 | 2023 | |||||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||
CURRENT LIABILITIES: | ||||||
Trade payables | $ | 3,045 | $ | 1,131 | ||
Deferred revenues | 1,583 | 997 | ||||
Operating lease liabilities | 504 | 111 | ||||
Other accounts payable and accrued expenses | 6,052 | 6,300 | ||||
Current maturity of long-term loan | 5,451 | 3,954 | ||||
Total current liabilities | 16,635 | 12,493 | ||||
NON-CURRENT LIABILITIES | ||||||
Operating lease liabilities | 765 | 885 | ||||
Long-term loan | 23,472 | 24,591 | ||||
Warrant liability | 5,968 | 240 | ||||
Other long-term liabilities | 25 | 36 | ||||
Total non-current liabilities | 30,230 | 25,752 | ||||
STOCKHOLDERS' EQUITY | ||||||
Common stock of | 4 | 3 | ||||
Preferred stock of | *) - | *) - | ||||
Additional paid-in capital | 462,358 | 407,502 | ||||
Accumulated deficit | (390,343) | (349,361) | ||||
Total stockholders' equity | 72,019 | 58,144 | ||||
Total liabilities and stockholders' equity | $ | 118,884 | $ | 96,389 | ||
DARIOHEALTH CORP. AND ITS SUBSIDIARIES | ||||||
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS | ||||||
Year ended | ||||||
December 31, | ||||||
2024 | 2023 | |||||
Revenues: | ||||||
Services | $ | 20,197 | $ | 13,084 | ||
Consumer hardware | 6,843 | 7,268 | ||||
Total revenues | 27,040 | 20,352 | ||||
Cost of revenues: | ||||||
Services | 3,606 | 4,679 | ||||
Consumer hardware | 5,139 | 5,303 | ||||
Amortization of acquired intangible assets | 5,028 | 4,386 | ||||
Total cost of revenues | 13,773 | 14,368 | ||||
Gross profit | 13,267 | 5,984 | ||||
Operating expenses: | ||||||
Research and development | $ | 24,179 | $ | 20,248 | ||
Sales and marketing | 26,350 | 23,785 | ||||
General and administrative | 20,482 | 18,140 | ||||
Total operating expenses | 71,011 | 62,173 | ||||
Operating loss | 57,744 | 56,189 | ||||
Total financial expenses (income), net | (13,145) | 3,174 | ||||
Loss before taxes | 44,599 | 59,363 | ||||
Income Tax | (1,852) | 64 | ||||
Net loss | $ | 42,747 | $ | 59,427 | ||
Deemed dividend (contribution) | $ | (1,765) | $ | 4,084 | ||
Net loss attributable to common shareholders | $ | 40,982 | $ | 63,511 | ||
Net loss per share: | ||||||
Basic and diluted loss per share of common stock | $ | 0.61 | $ | 1.93 | ||
Weighted average number of common stock used in computing basic and diluted | 49,039,410 | 28,371,979 | ||||
DARIOHEALTH CORP. AND ITS SUBSIDIARIES | ||||||
CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||||
Year ended | ||||||
December 31, | ||||||
2024 | 2023 | |||||
Cash flows from operating activities: | ||||||
Net loss | $ | (42,747) | $ | (59,427) | ||
Adjustments required to reconcile net loss to net cash used in operating activities: | ||||||
Stock-based compensation | 15,796 | 19,701 | ||||
Depreciation and impairment | 1,327 | 473 | ||||
Change in operating lease right of use assets | 907 | 239 | ||||
Amortization of acquired intangible assets | 6,100 | 4,512 | ||||
Decrease in trade receivables, net | 1,680 | 3,261 | ||||
Increase in other accounts receivable, prepaid expense and long-term assets | (80) | (426) | ||||
Decrease in inventories | 308 | 2,894 | ||||
Decrease in trade payables | (496) | (1,191) | ||||
Decrease in other accounts payable and accrued expenses | (3,483) | (256) | ||||
Decrease in deferred revenues | (156) | (323) | ||||
Change in operating lease liabilities | (1,150) | (124) | ||||
Change in fair value of warrant liability | (16,504) | (670) | ||||
Non-Cash financial expenses | 516 | 1,198 | ||||
Other | (580) | (240) | ||||
Net cash used in operating activities | (38,562) | (30,379) | ||||
Cash flows from investing activities: | ||||||
Purchase of property and equipment | (138) | (584) | ||||
Purchase of short-term investments | — | (4,996) | ||||
Proceeds from redemption of short-term investments | — | 5,033 | ||||
Payments for business acquisitions, net of cash acquired | (8,796) | — | ||||
Net cash used in investing activities | (8,934) | (547) | ||||
Cash flows from financing activities: | ||||||
Proceeds from issuance of common stock, net of issuance costs | — | 1,614 | ||||
Proceeds from issuance of preferred stock, net of issuance costs | 38,531 | 14,868 | ||||
Proceeds from borrowings on credit agreement | — | 29,604 | ||||
Repayment of long-term loan | — | (27,833) | ||||
Net cash provided by financing activities | 38,531 | 18,253 | ||||
Decrease in cash, cash equivalents and restricted cash and cash equivalents | (8,965) | (12,673) | ||||
Effect of exchange rate differences on cash, cash equivalents and restricted cash and cash equivalents | (68) | — | ||||
Cash, cash equivalents and restricted cash and cash equivalents at beginning of period | 36,797 | 49,470 | ||||
Cash, cash equivalents and restricted cash and cash equivalents at end of period | $ | 27,764 | $ | 36,797 | ||
Supplemental disclosure of cash flow information: | ||||||
Cash paid during the period for interest on long-term loan | $ | 3,927 | $ | 4,031 | ||
Non-cash activities: | ||||||
Right-of-use assets obtained in exchange for lease liabilities | $ | 428 | $ | 136 | ||
Exercise of pre-funded warrant to common stock upon acquisition | $ | 2,225 | $ | - | ||
Reconciliation of Operating Loss, Net Loss and Operating Expenses to Adjusted | ||||||||
Operating Loss, Net Loss and Operating Expenses (Non-GAAP) | ||||||||
Three months ended December 31, 2024 | ||||||||
GAAP | Stock-Based | Amortization of | Non-GAAP | |||||
Cost of Revenues | $ | 3,402 | (8) | (1,302) | 2,092 | |||
Gross Profit | 4,202 | 8 | 1,302 | 5,512 | ||||
Research and development | 5,281 | (985) | (51) | 4,245 | ||||
Sales and Marketing | 5,575 | (536) | (325) | 4,714 | ||||
General and Administrative | 5,014 | (1,061) | (474) | 3,479 | ||||
Total Operating Expenses | 15,870 | (2,582) | (850) | 12,438 | ||||
Operating Loss | $ | (11,668) | 2,590 | 2,152 | (6,926) | |||
Financing expenses | (2,191) | - | - | (2,191) | ||||
Income Tax | 155 | 155 | ||||||
Net Loss | $ | (9,632) | 2,590 | 2,152 | (4,890) | |||
Reconciliation of Operating Loss, Net Loss and Operating Expenses to Adjusted | ||||||||
Operating Loss, Net Loss and Operating Expenses (Non-GAAP) | ||||||||
Three months ended December 31, 2023 | ||||||||
GAAP | Stock-Based | Amortization of | Non-GAAP | |||||
Cost of Revenues | $ | 3,484 | (266) | (1,118) | 2,100 | |||
Gross Profit | 132 | 266 | 1,118 | 1,516 | ||||
Research and development | 4,196 | (90) | (21) | 4,085 | ||||
Sales and Marketing | 4,622 | (918) | (42) | 3,662 | ||||
General and Administrative | 5,529 | (3,120) | (267) | 2,142 | ||||
Total Operating Expenses | 14,347 | (4,128) | (330) | 9,889 | ||||
Operating Loss | $ | (14,215) | 4,394 | 1,448 | (8,373) | |||
Financing expenses | 6 | - | 6 | |||||
Income Tax | 64 | 64 | ||||||
Net Loss | $ | (14,285) | 4,394 | 1,448 | (8,443) | |||
Reconciliation of Operating Loss, Net Loss and Operating Expenses to Adjusted | ||||||||
Operating Loss, Net Loss and Operating Expenses (Non-GAAP) | ||||||||
Twelve months ended December 31, 2024 | ||||||||
GAAP | Stock-Based | Amortization of | Non-GAAP | |||||
Cost of Revenues | $ | 13,773 | (13) | (5,086) | 8,674 | |||
Gross Profit | 13,267 | 13 | 5,086 | 18,366 | ||||
Research and development | 24,179 | (3,296) | (238) | 20,645 | ||||
Sales and Marketing | 26,350 | (4,890) | (1,183) | 20,277 | ||||
General and Administrative | 20,482 | (7,597) | (1,649) | 11,236 | ||||
Total Operating Expenses | 71,011 | (15,783) | (3,070) | 52,158 | ||||
Operating Loss | $ | (57,744) | 15,796 | 8,156 | (33,792) | |||
Financing expenses | (13,145) | - | - | (13,145) | ||||
Income Tax | (1,852) | (1,852) | ||||||
Net Loss | $ | (42,747) | 15,796 | 8,156 | (18,795) | |||
Reconciliation of Operating Loss, Net Loss and Operating Expenses to Adjusted | ||||||||
Operating Loss, Net Loss and Operating Expenses (Non-GAAP) | ||||||||
Twelve months ended December 31, 2023 | ||||||||
GAAP | Stock-Based | Amortization of | Non-GAAP | |||||
Cost of Revenues | $ | 14,368 | (327) | (4,490) | 9,551 | |||
Gross Profit | 5,984 | 327 | 4,490 | 10,801 | ||||
Research and development | 20,248 | (3,803) | (78) | 16,367 | ||||
Sales and Marketing | 23,785 | (6,468) | (171) | 17,146 | ||||
General and Administrative | 18,140 | (9,103) | (374) | 8,663 | ||||
Total Operating Expenses | 62,173 | (19,374) | (623) | 42,176 | ||||
Operating Loss | $ | (56,189) | 19,701 | 5,113 | (31,375) | |||
Financing expenses | 3,174 | - | - | 3,174 | ||||
Income Tax | 64 | 64 | ||||||
Net Loss | $ | (59,427) | 19,701 | 5,113 | (34,613) | |||
DarioHealth Corporate Contact
Mary Mooney
VP Marketing
Mary@dariohealth.com
+1-312-593-4280
DarioHealth Investor Relations Contact
Kat Parrella
Investor Relations Manager
kat@dariohealth.com
+315-378-6922
Media Contact:
Scott Stachowiak
Scott.Stachowiak@russopartnersllc.com
+1-646-942-5630
Logo - https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/dariohealth-reports-fourth-quarter-and-full-year-2024-financial-and-operating-results-302396845.html
SOURCE DarioHealth Corp.
FAQ
What was DarioHealth's (DRIO) revenue growth in 2024?
How many new clients did DRIO add in 2024?
What is DRIO's projected timeline for operational cash flow breakeven?
How much did DRIO's B2B2C recurring revenue grow in Q4 2024?
What was DRIO's gross profit margin in Q4 2024?
